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In achieving the goal of malaria eradication, vaccines
could play a crucial role. Current attempts to develop
malaria vaccines are primarily focused on Plamosdium
falciparum and are directed towards reducing morbidity
and mortality. This is the case of the RTS,S vaccine can-
didate, the most developed at the moment and currently
undergoing the final analysis of a multicentric, interna-
tional Phase III clinical trial. Continued support for these
efforts is essential, but if malaria vaccines are to be used
as part of a repertoire of tools for malaria eradication,
they will need to have an impact on malaria transmission,
contributing to lower the reproductive rate to less than
one.
The consultative group on vaccines of the Malaria Eradi-
cation Research Agenda (malERA) initiative identified key
features of vaccines especially suited for malaria eradica-
tion. The group introduced the concept of “Vaccines that
Interrupt Malaria Transmission” (VIMTs), broadening the
classical definition of Transmission Blocking Vaccines
(TBVs) -that target sexual and mosquito stages of the
parasite-, in order to also include any other parasite life
stages that may interrupt transmission of malaria. This
would include pre-erythrocytic and asexual stage vaccines
to reduce prevalence and densities of sexual forms of the
parasite, as well as vaccines against mosquito gut antigens
impeding parasite development in the vector.
Moreover, malaria eradication would necessarily need
to target not only P. falciparum but also P. vivax, for
which therapeutic vaccines against hypnozoites or pre-
ventive vaccines with effect against multiple parasite
stages could have enormous impact.
Development of VIMTs require the advancement of
basic understanding of interactions of the malaria para-
site with humans and vectors, as well as the development
of tools to measuring infectivity at the individual level
and assessing transmission within a given population.
VIMTs may have primarily an effect at the population
level and could be crucial not only for eradication, but
also in areas where malaria control is still the main issue
to be addressed. In order to accelerate the actual imple-
mentation of such vaccines, it is also important to
address regulatory issues and to develop appropriate
delivery platforms.
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